FORUM Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 830
- Registration Number
- NCT01714713
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 753
- Registration Number
- NCT01714661
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
Phase 2
Completed
- Conditions
- Mild Cognitive ImpairmentAlzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 52
- Registration Number
- NCT01661673
- Locations
- 🇺🇸
Glendale Adventist Medical Center, Glendale, California, United States
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
Phase 1
Completed
- Conditions
- SchizophreniaSchizoaffective DisorderCentral Nervous System Diseases
- Interventions
- Drug: PlaceboDrug: EVP-6124 (1.0 mg/day)Drug: EVP-6124 (0.3 mg/day)Drug: Antipsychotic therapy
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2012-06-21
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 21
- Registration Number
- NCT01556763
- Locations
- 🇺🇸
Clinical Research Institute, Wichita, Kansas, United States
Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects
Phase 1
Completed
- Conditions
- Cardiac RepolarizationHealthy Subjects
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 60
- Registration Number
- NCT01487135
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer's DiseaseCentral Nervous System DiseasesCognition
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 409
- Registration Number
- NCT01073228
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
🇷🇸Clinical Site 2, Belgrade, Serbia
🇺🇸Renstar Medical Research, Ocala, Florida, United States
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
Phase 2
Completed
- Conditions
- SchizophreniaCentral Nervous System DiseasesCognition
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 317
- Registration Number
- NCT00968851
- Locations
- 🇺🇸
CRI Worldwide, Willingboro, New Jersey, United States
🇷🇸Clinical Site 1, Belgrade, Serbia
🇺🇸Alexian Brothers Behavioral Health, Hoffman Estates, Illinois, United States
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer's DiseaseCentral Nervous System Diseases
- Interventions
- Drug: EVP-6124 (0.1 mg/day)Drug: EVP-6124 (1.0 mg/day)Drug: EVP-6124 (0.3 mg/day)
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 49
- Registration Number
- NCT00766363
- Locations
- 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
🇺🇸Global Medical Institutes, LLC, Princeton, New Jersey, United States
🇺🇸Pacific Research Network, Inc., San Diego, California, United States
© Copyright 2025. All Rights Reserved by MedPath